Find a Trial

Trial Results


26 protocol(s) meet the specified criteria
A011401OPEN TO ACCRUAL
RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER
A011502OPEN TO ACCRUAL
A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL
CTO-17-101OPEN TO ACCRUAL
Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
CTO-20190131OPEN TO ACCRUAL
A Phase I, Multicenter, Open-label, Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects with Advanced Solid Tumors
CTO-BTCRC-BRE18-337OPEN TO ACCRUAL
Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337
CTO-EA1181OPEN TO ACCRUAL
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
CTO-EAZ171OPEN TO ACCRUAL
Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women
CTO-NYU-S17-00890OPEN TO ACCRUAL
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer (IBC)
CTO-ODO-TE-B202OPEN TO ACCRUAL
A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer
EA1131OPEN TO ACCRUAL
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
IUCRO-0514OPEN TO ACCRUAL
Collection Of Specimens And Clinical Data To Create A Biorepository For Metastatic Breast Cancer
IUSCC-0595OPEN TO ACCRUAL
A Pilot Study Identifying the Impact of Social-Environmental Challenges and Cumulative Life Stress on Treatment-Related Behaviors and Satisfaction with Care in African American Breast Cancer Patients
IUSCC-0659OPEN TO ACCRUAL
Assessing tobacco use and cessation support among patients with non-tobacco related cancers
IUSCC-0678OPEN TO ACCRUAL
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
IUSCC-0680OPEN TO ACCRUAL
Effect of low intensity vibration (LIV) on aromatase inhibitor- induced musculoskeletal dysfunction in early stage breast cancer survivors
J11155OPEN TO ACCRUAL
Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer
J13104OPEN TO ACCRUAL
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)
MCC19117OPEN TO ACCRUAL
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
PSY-IIR-IUSCC-0698OPEN TO ACCRUAL
Telephone Support for Metastatic Breast Cancer Patients
RADY-GU-SAYKIN-TLCOPEN TO ACCRUAL
Older Breast Cancer Patients: Risk for Cognitive Decline
RAON-CCTG-MA39OPEN TO ACCRUAL
A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
S1418/BR006OPEN TO ACCRUAL
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
TBCRC034OPEN TO ACCRUAL
The incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in patients diagnosed with Flat Epithelial Atypia (FEA) or Intraductal Papilloma without Atypia (IPWA) by Core Needle Biopsy
TBCRC044OPEN TO ACCRUAL
A Randomized Phase II Study of Pembrolizumab, an anti-PD (programmed cell death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease
TBCRC045OPEN TO ACCRUAL
A RANDOMIZED, PHASE II STUDY COMPARING TRASTUZUMAB AND VINORELBINE IN COMBINATION WITH AVELUMAB OR AVELUMAB AND UTOMILUMAB (41BB/CD137 AGONIST), IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER WHO HAVE PROGRESSED ON PRIOR TRASTUZUMAB AND PERTUZUMAB: The "AVIATOR Study
TBCRCADM-002OPEN TO ACCRUAL
Translational Breast Cancer Research Consortium Biospecimen & Outcomes Repository